Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma.

Dana L CaseyLeonard H WexlerKenneth L PitterRobert M SamsteinEmily K SlotkinSuzanne L Wolden

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

High TMB was associated with worse clinical outcomes in patients with RMS. With further validation, TMB and other genomic classifiers may be combined with traditional clinicopathologic risk factors to guide risk stratification and ultimately treatment decisions.

Keyphrases

risk factors
copy number
combination therapy